- Home
- DHT vs ARQT Comparison
DHT vs ARQT Comparison
Compare DHT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | ARQT |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | 354 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DHT | ARQT |
|---|---|---|
| Price | $21.66 | $28.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $19.33 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.5M | 2.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $8.85 | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | ★ $12.73 | $865.33 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $10.83 | $16.68 |
| 52 Week High | $23.56 | $31.77 |
Technical Indicators
Market Signals| Indicator | DHT | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 56.61 |
| Support Level | $16.65 | $24.91 |
| Resistance Level | N/A | $27.57 |
| Average True Range (ATR) | 0.76 | 1.13 |
| MACD | 0.04 | 0.34 |
| Stochastic Oscillator | 45.58 | 85.34 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.